Drug Profile
Research programme: HIV immunotherapeutics - Oxxon
Alternative Names: Hi-8 HIVLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Oxxon Therapeutics
- Class Recombinant fusion proteins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in HIV-infections in United Kingdom
- 26 Jul 2004 Preclinical trials in HIV infections treatment in United Kingdom (unspecified route)